Angion Biomedica Corp. (ANGN)

NASDAQ: ANGN · IEX Real-Time Price · USD
0.940
+0.020 (2.21%)
Oct 4, 2022 4:30 PM EDT - Market closed
2.21%
Market Cap 28.31M
Revenue (ttm) 29.70M
Net Income (ttm) -24.19M
Shares Out 30.11M
EPS (ttm) -1.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 35,529
Open 0.940
Previous Close 0.920
Day's Range 0.914 - 0.970
52-Week Range 0.870 - 9.420
Beta n/a
Analysts Sell
Price Target 4.85 (+415.9%)
Earnings Date Nov 10, 2022

About ANGN

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and... [Read more...]

Industry Biotechnology
IPO Date Feb 5, 2021
Employees 37
Stock Exchange NASDAQ
Ticker Symbol ANGN
Full Company Profile

Financial Performance

In 2021, ANGN's revenue was $28.31 million, an increase of 883.06% compared to the previous year's $2.88 million. Losses were -$54.57 million, -31.87% less than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for ANGN stock is "Sell." The 12-month stock price forecast is 4.85, which is an increase of 415.90% from the latest price.

Price Target
$4.85
(415.90% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Angion Provides Corporate Update and Reports Second Quarter 2022 Financial Results

UNIONDALE, N.Y. , Aug. 15, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small ...

1 month ago - GlobeNewsWire

Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving Shareholder Value

UNIONDALE, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule ...

2 months ago - GlobeNewsWire

Angion Biomedica Pulls The Plug On Another Kidney Disease Trial - Read Why

Angion Biomedica Corp (NASDAQ: ANGN) has discontinued the JUNIPER Phase 2 trial of ANG-3070, an oral tyrosine kinase inhibitor, in primary proteinuric kidney diseases, specifically focal segmental glome...

3 months ago - Benzinga

Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease

UNIONDALE, N.Y., June 29, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule ...

3 months ago - GlobeNewsWire

Angion Provides Corporate Update and Reports First Quarter 2022 Financial Results

-- Ended the quarter with $73M in cash and cash equivalents sufficient to fund operations well into 2023

4 months ago - GlobeNewsWire

Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis

-- The FDA has accepted an IND application supporting clinical development of ANG-3070 in IPF

4 months ago - GlobeNewsWire

Angion Announces Participation in Upcoming Investment Conference

UNIONDALE, N.Y., May 12, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule t...

4 months ago - GlobeNewsWire

5 Biotech Stocks Set to Outpace Q1 Earnings Estimates

Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.

Other symbols: APLTBOLTIKNALABP
4 months ago - Zacks Investment Research

Angion Provides Corporate Update and Reports Full Year 2021 Financial Results

-- Enrollment continues in Phase 2 JUNIPER trial of ANG-3070 for the treatment of patients with primary proteinuric kidney diseases

6 months ago - GlobeNewsWire

Angion Announces Participation in Upcoming Investment Conferences

UNIONDALE, N.Y., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule ...

7 months ago - GlobeNewsWire

Angion Provides Corporate Update and Announces Participation in Upcoming Investor Conference

-- First patient enrolled in the Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases

9 months ago - GlobeNewsWire

Angion (ANGN) Kidney Drug Misses Third Study Goal in 2021

Angion's (ANGN) phase II study evaluating ANG-3777 in cardiac surgery-associated acute kidney injury fails to achieve the primary endpoint.

9 months ago - Zacks Investment Research

Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated ac...

ST. GALLEN, Switzerland & UNIONDALE, N.Y.--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced results fro...

9 months ago - Business Wire

Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surgery-Associated Acu...

-- Angion to host a conference call today at 4:30 p.m. EST

9 months ago - GlobeNewsWire

Angion Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Ended the quarter with nearly $103M in cash and cash equivalents Ended the quarter with nearly $103M in cash and cash equivalents

10 months ago - GlobeNewsWire

Angion Presents Multiple Posters on ANG-3070 at Kidney Week 2021, Including Preclinical Data and Design of Upcoming P...

UNIONDALE, N.Y., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small...

11 months ago - GlobeNewsWire

Angion to Participate in Upcoming Investment Conference

UNIONDALE, N.Y., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small...

11 months ago - GlobeNewsWire

Why Did Angion Biomedica's Shares tumble Premarket Today?

After flopping a test in COVID-19 earlier this year, Angion Biomedica Corp's (NASDAQ: ANGN) lead candidate drug has hit a setback again, this time in kidney transplant patients. Related:   Angion Stock ...

11 months ago - Benzinga

Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant pat...

ST. GALLEN, Switzerland & UNIONDALE, NY--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced that the phas...

11 months ago - Business Wire

Angion and Vifor Pharma Report Topline Results from Phase 3 Trial of ANG-3777 in Kidney Transplant Patients at Risk f...

Angion to host a conference call at 4:30 p.m. EDT Angion to host a conference call at 4:30 p.m. EDT

11 months ago - GlobeNewsWire

Angion to Present Multiple Posters at Kidney Week 2021

UNIONDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small...

11 months ago - GlobeNewsWire

Angion Hosting Research & Development Day on ANG-3070 for the Treatment of Lung and Kidney Fibrosis

UNIONDALE, N.Y., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel sma...

1 year ago - GlobeNewsWire

Angion to Participate in Upcoming September Investment Conferences

UNIONDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel smal...

1 year ago - GlobeNewsWire

Angion Biomedica Shares Moving Higher On Encouraging Results From Early Stage Trial Of Fibrotic Disease Candidate

Angion Biomedica Corp (NASDAQ: ANGN) has announced positive results from its Phase 1 study in healthy volunteers for ANG-3070 for fibrotic diseases.  In the 97-volunteer trial, ANG-3070 achieved drug ex...

1 year ago - Benzinga

Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate P...

UNIONDALE, N.Y., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small...

1 year ago - GlobeNewsWire